Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%0700.HK-5.82%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.24%ORCL-0.97%3988.HK-0.36%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.17%0857.HK-2.43%UNH-10.21%1288.HK-1.64%PM-0.85%0005.HK-2.03%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.58%AUDUSD-1.47%EURAUD+0.95%AUDCAD-0.92%AUDCHF-0.90%GBPAUD+0.88%AUDNZD-0.88%NZDJPY-0.72%GBPJPY-0.70%CHFJPY-0.68%CADJPY-0.67%EURJPY-0.65%USDCHF+0.60%NZDUSD-0.59%GBPUSD-0.57%USDCAD+0.57%AUDSGD-0.56%EURUSD-0.52%AUDDKK-0.51%GBPTRY+0.41%AUDNOK-0.40%USDZAR+0.33%GBPHKD+0.32%NZDMXN+0.32%USDMXN+0.32%USDTHB+0.30%GBPMXN-0.28%EURZAR+0.24%GBPZAR+0.21%USDTRY+0.21%USDNOK+0.19%USDILS+0.16%CHFNOK+0.14%USDJPY-0.13%USDSEK+0.13%USDPLN+0.12%USDCNH-0.12%EURCNH-0.12%EURNOK+0.11%NOKJPY-0.10%EURHKD-0.09%USDDKK+0.08%CHFSEK+0.08%GBPSGD-0.08%EURCHF+0.07%SGDJPY+0.07%EURNZD+0.06%EURGBP+0.05%EURSGD-0.05%NZDSGD+0.05%EURSEK+0.05%NZDCAD-0.05%EURCZK+0.04%EURPLN+0.04%USDCOP-0.04%EURCAD+0.03%USDSGD+0.03%GBPCAD-0.03%CADCHF+0.03%PLNJPY-0.03%NZDCHF-0.02%CHFSGD-0.02%GBPCHF+0.02%GBPNZD+0.02%USDHKD-0.01%EURDKK0.00%UKOIL+0.52%W1-0.51%XNGUSD-0.46%C1-0.41%XPTUSD-0.38%USOIL+0.32%HG1-0.31%S1-0.22%GAUUSD-0.11%XAUUSD-0.11%COTTON+0.08%XAGUSD+0.06%BTCUSD-3.46%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.77%ZECUSDT-6.58%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.12%XLMUSD-3.50%BCHUSDT-3.41%LTCUSD+47.50%UNIUSD-2.84%SUIUSD-2.76%TONUSD+59.18%HBARUSDT-4.95%TAOUSDT-2.97%AAVEUSD-3.45%ONDOUSDT-5.16%ICPUSDT-1.57%DOTUSDT-3.63%WLDUSDT-3.57%ARBUSDT-5.49%ATOMUSDT-2.24%INJUSDT-7.58%STXUSDT-2.75%PYTHUSDT-0.96%TIAUSDT-2.82%FETUSDT-4.16%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-2.63%IOTAUSDT-2.46%POLUSDT-1.89%WIFUSDT-2.25%AXSUSDT-2.76%EOSUSDT-3.95%IMXUSDT-3.36%FARTCOINUSDT-6.28%GALAUSDT-1.65%DYDXUSDT-2.47%ORDIUSDT-2.25%NOTUSDT+0.86%RONINUSDT-2.92%
LP

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ • Healthcare

$298.7
+$4.89 (+1.7%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$295
Day Range$292.94 - $301.93
Avg. Volume (3M)231.6K
Market Cap$5.9B
P/E Ratio115.3
52 Week Range
$175.89$326.63

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$78.7M100%
Gross Profitminus cost of goods$76M97%

In plain terms: out of every $100 in revenue, Ligand Pharmaceuticals Incorporated currently loses $36.

Fundamentals & Financials

Revenue (TTM)
$253.8M
Net Income (TTM)
$51.4M
EPS (TTM)
$2.59
ROA (TTM)
2.3%
Current Ratio
1.22
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-11.4%Q2 2026$1.63
+17.9%Q3 2026$2.37
+14.6%Q4 2026$2.67

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +14.6%

Ligand Pharmaceuticals beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, with adjusted EPS of $2.67 topping the $2.33 estimate (+14.6%) even as revenue fell 31.8% year over year to roughly $78.7 million (down from about $115.5 million a year ago) and still came in above consensus at $78.7 million versus $77.0 million (+2.3%). On the bottom line, adjusted EPS declined 13.6% from $3.09 a year ago, and net income was not provided with the preliminary figures. The company’s model centers on licensing and supporting a portfolio of marketed medicines and its Captisol formulation technology across areas including oncology, vaccines, central nervous system, and anti-infective products. For the next period, consensus calls for EPS of $3.07 on revenue of $96.9 million.

View full earnings history

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that licenses and supports a portfolio of marketed medicines and formulation technology for pharmaceutical companies worldwide. Its business spans oncology, vaccines, central nervous system, anti-infective, cardiovascular, and bone-health products, and generated $268.1 million of revenue in FY2025.

Name
Ligand Pharmaceuticals Incorporated
CEO
Todd C. Davis
Industry
Healthcare
Year Founded
1987
Employees
47

Today's Snapshot

AI-generated

LGND closed 1.7% above yesterday's close, outperforming a weaker sector. Trading was busier than usual, with volume roughly twice its usual level.

Trading Volume

Above 10d avg 198.0K

378.7K

vs S&P 500 Today

Outperforming Market

+1.93%

Updated: November 18, 2026 at 21:17 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
LGND presents a neutral intermediate picture with price above the 200-day averages but below several short- and medium-term moving averages, leaving a mixed bias around the pivot just under current levels. Momentum is mildly negative given a slightly negative MACD and low CCI, and the RSI sits in the lower range without oversold extremes. Trend strength is weak per ADX and volatility is moderate, while on-balance volume is positive, suggesting some buying support beneath price. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$261.04 - $306.96
    Sell
  • RSI (14)44.92
    Neutral
  • Stochastic %K (14, 3, 3)13.83
    Buy
  • MACD Level (12, 26)-0.22
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.